Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...
Axon is rated a 'Buy' due to strong recurring revenue growth, expanding AI integration, and a dominant market position in security technology. AXON's Q2 2025 revenue rose 33% YoY to $669 million, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results